Circulating irisin levels are positively associated with endothelium-dependent vasodilation in newly diagnosed type 2 diabetic patients without clinical angiopathy

Atherosclerosis

Volumn 235, Issue 2, 2014, Pages 328-333

  Xiang, Lin ^a,b   Xiang, Guangda ^b   Yue, Ling ^b   Zhang, Junxia ^b   Zhao, Linshuang ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

Circulating irisin; Endothelial dysfunction; Type 2 diabetes

Indexed keywords

IRISIN; MUSCLE PROTEIN; UNCLASSIFIED DRUG; FIBRONECTIN; FNDC5 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHINESE; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; ULTRASOUND; VASODILATATION; BLOOD; BLOOD FLOW; INSULIN RESISTANCE; LESIONS AND DEFECTS; PATHOPHYSIOLOGY;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DILATATION, PATHOLOGIC; FEMALE; FIBRONECTINS; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; REGIONAL BLOOD FLOW; VASODILATION;

EID: 84921637862     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.04.036     Document Type: Article

References (26)

1. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
2. Calles-Escandon J., Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001, 22:36-52.
3. Versari D., Daghini E., Virdis A., Ghiadoni L., Taddei S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009, 32(Suppl.2):S314-S321.
4. Xiang G.D., Wang Y.L. Regular aerobic exercise training improves endothelium-dependent artery dilation in patients with impaired fasting glucose. Diabetes Care 2004, 27:801-802.
5. Xiang G.D., Wu Y.H. Apolipoprotein e4 allele and endothelium- dependent arterial dilation in type 2 diabetes mellitus without angiopathy. Diabetologia 2003, 46:514-519.
6. Pedersen B.K., Febbraio M.A. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 2008, 88:1379-1406.
7. Iijima K., Iimuro S., Shinozaki T., Ohashi Y., Sakurai T., Umegaki H., et al. Lower physical activity is a strong predictor of cardiovascular events in elderly patients with type 2 diabetes mellitus beyond traditional risk factors: the Japanese Elderly Diabetes Intervention Trial. Geriatr Gerontol Int 2012, (Suppl.1):77-87. Japanese Elderly Diabetes Intervention Trial Investigator Group.
8. Gillies C.L., Abrams K.R., Lambert P.C., Cooper N.J., Sutton A.J., Hsu R.T., et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007, 334(7588):299.
9. Laaksonen D.E., Lindström J., Lakka T.A., Eriksson J.G., Niskanen L., Wikström K., et al. Finnish diabetes prevention study. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes 2005, 54:158-165.
10. Pedersen B.K., Febbraio M.A. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 2012, 8:457-465.
11. Charos A.E., Reed B.D., Raha D., Szekely A.M., Weissman S.M., Snyder M. Ahighly integrated and complex PPARGC1A transcription factor binding network in HepG2 cells. Genome Res 2012, 22:1668-1679.
12. Handschin C., Spiegelman B.M. The role of exercise and PGC1 alpha in inflammation and chronic disease. Nature 2008, 454:463-469.
13. Boström P., Wu J., Jedrychowski M.P., Korde A., Ye L., Lo J.C., et al. APGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012, 481:463-468.
14. Barbatelli G., Murano I., Madsen L., Hao Q., Jimenez M., Kristiansen K., et al. The emergence of cold-induced brown adipocytes in mouse white fat depots is determined predominantly by white to brown adipocyte transdifferentiation. Am J Physiol Endocrinol Metab 2010, 298:E1244-1253.
15. Enerbäck S. Human brown adipose tissue. Cell Metab 2010, 11:248-252.
16. Muniyappa R., Sowers J.R. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord 2013, 14:5-12.
17. Timmons J.A., Pedersen B.K. The importance of brown adipose tissue. NEngl J Med 2009, 361:415-416.
18. Xiang G.D., Xu L., Zhao L.S., Yue L., Hou J. The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes 2006, 55:2126-2131.
19. Soyal S., Krempler F., Oberkofler H., Patsch W. PGC-1 alpha: a potent transcriptional cofactor involved in the pathogenesis of type 2 diabetes. Diabetologia 2006, 49:1477-1488.
20. Liang H., Ward W.F. PGC-1 alpha: a key regulator of energy metabolism. Adv Physiol Educ 2006, 30:145-151.
21. Kelly D.P. Medicine. Irisin, light my fire. Science 2012, 336:42-43.
22. Villarroya F. Irisin, turning up the heat. Cell Metab 2012, 15:277-278.
23. Liu J.J., Wong M.D.S., Toy W.C., Tan C.S.H., Liu S., Ng X.W., et al. Lower circulating irisin is associated with type 2 diabetes mellitus. JDiabet Complications 2013, 27:365-369.
24. Choi Y.K., Kim M.K., Bae K.H., Seo H.A., Jeong J.Y., Lee W.K., et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 2013, 100:96-101.
25. Zhang H.J., Zhang X.F., Ma Z.M., Pan L.L., Chen Z., Han H.W., et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. JHepatol 2013, 59:557-562.
26. Crujeiras A.B., Pardo M., Arturo R.R., Santiago N.C., Zulet M.A., Martínez J.A., et al. Longitudinal variation of circulating irisin after an energy restriction-induced weight loss and following weight regain in obese men and women. Am J Human Biol 2014, 26. 198-7.